PrECOG Cancer Research Group

PrECOG Cancer Research Group Innovative cancer research studies developed through industry partnerships and networks.

Supporting ECOG-ACRIN Cancer Research Group's efforts to advance cancer care

The PrE1702 research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-posit...
08/26/2025

The PrE1702 research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive in patients not participating in a clinical trial. Learn more: https://bit.ly/pre1702-study

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive in patients not participating in ...
08/19/2025

How well does osimertinib—with or without chemotherapy—work to control EGFR-positive in patients not participating in a clinical trial? The PrE1702 research study aims to find out. Learn more: https://bit.ly/pre1702-study

07/22/2025

Read more from our co-chairs on the importance of protecting public support for biomedical research: https://bit.ly/3IvxNQD

Breast Cancer Breakthrough Explained: A special type of immunotherapy is being studied by our cancer researchers. It is ...
06/25/2025

Breast Cancer Breakthrough Explained:

A special type of immunotherapy is being studied by our cancer researchers. It is a naturally occurring, non-pathogenic oncolytic virus with two key complementary actions when administered to patients intravenously. First, this drug stimulates anti-tumor immune responses; second, it enhances the immune system’s ability to recognize and respond to tumors.

Our researchers conducted a small clinical trial called BRACELET-1 to study the safety and efficacy of this oncolytic virus immunotherapy (called pelareorep) in 48 patients with HR+ HER2- metastatic breast cancer. The trial studied pelareorep combined with paclitaxel chemotherapy, with or without the checkpoint inhibitor avelumab, for patients whose disease progressed after first-line treatment.

“Our study results support further investigation of the paclitaxel-pelareorep combination while monitoring acute toxicity. Until now, immunotherapy in patients with HR+ HER2- metastatic breast cancer has been largely unsuccessful, prompting the trial,” said Amy S. Clark, MD, a medical oncologist at Penn Medicine in Philadelphia and first author of the report.

More: bit.ly/BRACELET-1Results

research study PrE1702, led by Dr. Suzanne Cole of UT Southwestern, aims to discover if osimertinib with or without ch...
06/24/2025

research study PrE1702, led by Dr. Suzanne Cole of UT Southwestern, aims to discover if osimertinib with or without chemotherapy has the same benefits for patients receiving treatment outside of a as for those in a trial. Learn more: https://bit.ly/pre1702-study

Address

1818 Market Street, Suite 3000
Philadelphia, PA
19118

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+12157897001

Website

Alerts

Be the first to know and let us send you an email when PrECOG Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

PrECOG, LLC develops and leads research that provides new hope for patients and their families. This is accomplished through innovation, working with oncology research leaders, partnerships with research groups, and collaborations with industry partners. Our goal is to design, implement, and publish results for clinical trials that support the ever-evolving needs of patients with cancer and our underlying knowledge of cancer diseases.